Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 2:68:102375.
doi: 10.1016/j.eclinm.2023.102375. eCollection 2024 Feb.

Effect of human milk-based fortification in extremely preterm infants fed exclusively with breast milk: a randomised controlled trial

Georg Bach Jensen  1 , Magnus Domellöf  2 , Fredrik Ahlsson  3 , Anders Elfvin  4   5 , Lars Navér  6   7 , Thomas Abrahamsson  1
Affiliations

Effect of human milk-based fortification in extremely preterm infants fed exclusively with breast milk: a randomised controlled trial

Georg Bach Jensen et al. EClinicalMedicine. .

Erratum in

Abstract

Background: Mortality and severe morbidity remain high in extremely preterm infants. Human milk-based nutrient fortifiers may prevent serious complications and death. We aimed to investigate whether supplementation with human milk-based fortifier (HMBF), as compared to bovine milk-based fortifier (BMBF), reduced the incidence of the composite outcome of necrotising enterocolitis (NEC), sepsis, and mortality in extremely preterm infants exclusively fed human milk.

Methods: In this multicentre, randomised controlled trial at 24 neonatal units in Sweden, extremely preterm infants born between gestational week 22 + 0 and 27 + 6 fed exclusively human breast milk (mother's own and/or donor milk), were randomly assigned (1:1) to receive targeted fortification with either HMBF or BMBF. Randomisation was conducted before the enteral feeds reached 100 mL/kg/day, and was stratified by enrolment site, gestational age, singleton/twin, and sex. The allocation was concealed before inclusion, but after randomisation the study was not blinded for the clinical staff. For the NEC diagnosis, the study group was masked to an independent radiologist, and the final assessment of NEC and culture-proven sepsis was done by a blinded consensus panel review. The primary outcome was the composite of NEC stage II-III, culture-proven sepsis, and mortality from inclusion to discharge, no longer than postmenstrual week 44 + 0, in the intention-to-treat population (ClinicalTrials.gov, NCT03797157).

Findings: Between February 21st, 2019, and May 21st, 2021, 229 neonates were randomly assigned (115 HMBF, 114 BMBF). After exclusion of one infant due to parents' withdrawal of consent, 228 infants were included in the intention-to-treat analysis. Of the 115 infants assigned to HMBF, 41 (35.7%) fulfilled the criteria of either NEC, sepsis, or death, compared with 39 (34.5%) of 113 infants assigned to BMBF (OR 1.05, 95% CI 0.61-1.81, p = 0.86). Adverse events did not differ significantly between groups.

Interpretation: Supplementation with HMBF, as compared with BMBF, did not reduce the incidence of the composite outcome of NEC, sepsis, or death. Our results do not support routine supplementation with HMBF as a nutritional strategy to prevent NEC, sepsis, or death in extremely preterm infants exclusively fed human milk.

Funding: ALF grant, Prolacta Bioscience, Swedish Research Council, and Research Council for Southeast Sweden.

Keywords: Breast milk; Necrotising enterocolitis; Nutrient fortifier; Nutrition; Preterm infant; Sepsis.

PubMed Disclaimer

Conflict of interest statement

TA received a grant for the present study by Prolacta Bioscience, CA, USA. All other authors declare no competing interests. None of the investigators have any financial interest in Prolacta Bioscience.

Figures

Fig. 1
Fig. 1
Flow chart of the trial. HMBF = human milk-based fortifier. BMBF = bovine milk-based fortifier.
See this image and copyright information in PMC

References

    1. Perin J., Mulick A., Yeung D., et al. Global, regional, and national causes of under-5 mortality in 2000-19: an updated systematic analysis with implications for the sustainable development goals. Lancet Child Adolesc Health. 2022;6(2):106–115. - PMC - PubMed
    1. Chawanpaiboon S., Vogel J.P., Moller A.B., et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Glob Health. 2019;7(1):e37–e46. - PMC - PubMed
    1. Morgan A.S., Mendonca M., Thiele N., David A.L. Management and outcomes of extreme preterm birth. BMJ. 2022;376 - PMC - PubMed
    1. Norman M., Hallberg B., Abrahamsson T., et al. Association between year of birth and 1-year survival among extremely preterm infants in Sweden during 2004-2007 and 2014-2016. JAMA. 2019;321(12):1188–1199. - PMC - PubMed
    1. Lin P.W., Stoll B.J. Necrotising enterocolitis. Lancet. 2006;368(9543):1271–1283. - PubMed

Associated data